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BY-NC-ND license (http://creativecomBackground/Purpose: Recent studies suggest that hyperuricemia is a potential risk factor for
cardiovascular disease (CVD). Hyperuricemia is highly heritable and is associated with sex and
body weight. Previous genome-wide association studies have found that the ABCG2 single
nucleotide polymorphism (SNP) rs2231142 is an important genetic factor for increased uric
acid (UA) levels, and the degree of association between rs2231142 and hyperuricemia is
affected by both sex and ethnicity. This investigation aimed to analyze the association be-
tween ABCG2 polymorphisms and UA levels, as well as their interactions with sex and obesity
in Taiwanese.
Methods: Two genetic polymorphisms around the ABCG2 gene were genotyped in 459 patients.
Results: After adjusting for clinical covariates, the rs2231142 SNP was found significantly asso-
ciated with UA levels using a dominant inheritance model. Patients carrying the rs2231142-A
allele had a higher frequency of hyperuricemia than those with the rs2231142-CC allele. Sub-
group analysis revealed an association of rs2231142 with UA levels in male or obese patients,
and there was no association in nonobese female patients.have no conflicts of interest relevant to this article.
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ABCG2 gene polymorphisms and uric acid levels 19Conclusion: The rs2231142 SNP is associated with serum UA levels and hyperuricemia in Taiwa-
nese patients and it occurs predominantly in male or obese patients. Hyperuricemia might be
controlled differently by sex and obesity.
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Hyperuricemia is commonly caused by overproduction or
underexcretion of uric acid (UA).1 As a result of evolution,
humans and great apes are hyperuricemic.2 This is due to a
series of mutations in the uricase gene 20 to 15 million
years ago.3 In recent years, significant progress has been
made, and UA is found to contribute to gouty arthritis,
vascular damage, and cardiovascular disease (CVD).4e8
Nevertheless, there are conflicting reports regarding the
relationship between hyperuricemia and the risks of CVD.9
In a Taiwanese cohort study, hyperuricemia is identified as
a risk factor for stroke mortality in ethnic Han Chinese and
high-risk subgroups.10 The prevalence of hyperuricemia in
Taiwanese males and females is 42.1% and 27.4%,11 and is
higher in Taiwanese compared with other ethnic
groups.12,13
ABCG2 belongs to the G-family ABC transporters.14,15 It
is postulated to be a unidirectional secretory urate trans-
porter in the proximal renal tubule16 and gut.17 Recent
studies have shown association of the ABCG2 single nucle-
otide polymorphisms (SNPs) with various phenotypes,
including UA levels, gout, and low-density lipoprotein
cholesterol levels.18e25 A C-to-A mutation rs2231142, which
results in a Q-to-K substitution at position 141, has been
associated with hyperuricemia and gout.5,25,26 Mutant
ABCG2 protein with an engineered Q141K residue results in
a 53% reduction of urate transporter activity.16 Therefore,
in people carrying the rs2231142-A allele, hyperuricemia is
more likely to develop.
It is suggested that effect size of this SNP is greater in
males.22 Indeed, sexual differences in the regulation of
serum UA levels have been reported.8 Obesity is often
accompanied by hyperuricemia,27,28 but few studies have
addressed the association between obesity and genetic
variants involved in UA metabolism. The degree of associ-
ation between ABCG2 rs2231142 SNP and gout risk has been
found to vary with ethnicity.26 In this study, we examined
whether association between the ABCG2 SNPs and UA levels




After obtaining written informed consent, we recruited
study participants without history of major systemic dis-
eases, CVDs, and medication for hypertension orhyperuricemia. In total, we recruited 459 participants of
Han Chinese origin into this study.
Measurement of UA
We used uricase and peroxidase-catalyzed reactions to
measure UA concentrations. In brief, reaction mix was
freshly prepared by mixing four parts of solution I [59 mg/
dL N-ethyl-N-(2-hydroxy-3-sulfopropyl)-m-toluidine sodium
salt and 0.01% Triton X-100 (Sigma, St. Louis, MO, USA) in
0.1 mol/L phosphate buffer solution (PBS; 0.08 mol/L
Na2HPO4 and 0.02 mol/L NaH2PO4$H2O, pH 7.4; Merck,
Germany)] with one part of solution II [480 U/L uricase
(Sigma), 24 mg/dL 4-aminoantipyrine (Sigma) and 1300 U/L
horseradish peroxidase (Fluka, Switzerland) in 0.1 mol/L
PBS pH 7.4]. We then added 5 mL normal saline, interna-
tional standard of UA (10 mg/dL; Wako, Japan) or serum/
plasma samples into 200 mL of reaction mix, incubated for
20 minutes at room temperature, and measured absor-
bance at 545 nm using a 96-well plate reader (Spectra
MAX190, Molecular Devices, Sunnyvale, CA, USA). UA con-
centrations were calculated using a colorimetric method.
Intra-assay and interassay variabilities were controlled to
be 1.6w1.8% and 1.7w2.5%, respectively.
Genomic DNA extraction and genotyping
Genomic DNAwas extracted from leukocyteswith proteinase
K digestion, phenol/chloroform extraction, and isopropanol
precipitation. Primers were generated to amplify fragments
containing SNPs reported on GenePipe (http://genepipe.
ncgm.sinica.edu.tw/) and GeneCards (http://www.
genecards.org/). Genotyping for rs72552713 was performed
with polymerase chain reaction and restriction enzyme di-
gestions. Genotyping for rs2231142 was performed using
TaqMan SNP Genotyping Assays (ABI, Foster City, CA, USA).
Statistical analysis
Chi-square test was used to examine categorical data.
Characteristics of continuous variables were expressed as
means  standard deviations and tested by two-sample t-
test or analysis of variance (ANOVA). A general linear
model was applied to capture the major effect of each
polymorphism on phenotypic variable, with body mass
index (BMI), age, sex, and smoking status as confounding
covariates. Triglyceride was logarithmically transformed
to normality. A value of p < 0.05 using a two-sided test
was considered statistically significant. Analysis of





Mean  SD (n)
p p*
rs2231142 CC 6.02  1.56 (208)
CA 6.58  1.62 (202) 0.002 0.437
AA 6.37  1.65 (41)
CC 5.73  104 0.009
CAþAA 6.54  1.63 (243)
rs72552713 AG 6.80  2.09 (6) 0.463 0.163
GG 6.32  1.61 (440)
p, unadjusted; p*, adjusted for age, sex, body mass index, and
smoking status.
SD Z standard deviation; SNP Z single nucleotide poly-
morphism; UA Z uric acid.
20 S.-T. Cheng et al.deviation from HardyeWeinberg equilibrium and estima-
tion of linkage disequilibrium between polymorphisms
were performed using THESIAS (http://ecgene.net/
genecanvas/).29 Genetic association analyses were per-
formed using SPSS (IBM, USA) and Golden Helix (Bozeman,
MT, USA). Interactions between each SNP and UA levels,
sex, and obesity were tested with two-way ANOVA. When
interaction terms were significant, stratified analyses of
the interactive effects between genetic variants of the
SNPs and UA levels were performed while controlling for
confounding covariates. Statistical results were validated




Table 1 summarizes basic demographic characteristics of
the study participants. Although no difference in systolic
blood pressure, total cholesterol concentrations, and fre-
quency of hypertension or diabetes mellitus were observed,
many variables were different between different sexes.
Smokers were seen with a male predominance, and males
also had higher diastolic blood pressure, BMI, low-density
lipoprotein, triglycerides, and UA levels. In contrast, high-
density lipoprotein levels were higher in females.
Association of the ABCG2 SNPs with UA levels and
frequency of hyperuricemia
After adjusting for clinical covariates including age, sex,
BMI, and smoking status, rs2231142 was found significantly
associated with UA levels using a dominant inheritance
model, whereas no evidence of association between
rs72552713 and UA levels was found (Table 2). Carriers of
the rs2231142-A allele had significantly higher UA levels
compared with those carrying the CC allele. Patients car-
rying the rs2231142-A allele also had a higher frequency of
hyperuricemia (Figure 1).Table 1 Baseline characteristics of the study patients.
Total
Number of patients 459
Age, y 45.0  9.5
Hypertension, % 8.5
Systolic BP, mm Hg 112.6  15.4
Diastolic BP, mm Hg 74.8  9.7
Cholesterol, mg/dL 198.8  35.8
HDL cholesterol, mg/dL 55.6  14.0
LDL cholesterol, mg/dL 116.2  32.1
Triglycerides, mg/dL 140.5  115.0
BMI, kg/m2 24.2  3.4
Diabetes mellitus, % 3.7
Smokers, % 20.5
UA, mg/dL 6.3  1.6
Continuous variables are presented as mean  standard deviation.
tistical testing to meet the assumption of normal distributions; howe
BP Z blood pressure; HDL Z high-density lipoprotein; LDL Z low-deAssociation of the ABCG2 SNPs with UA levels and
frequency of hyperuricemia in obese and nonobese
patients
Hyperuricemia is associated with obesity.27,28 The effect
of obesity on UA levels in the rs2231142-CC carriers was
similar to that in the other two variant carriers, in
general and in either sex (Table 3). Obese patients car-
rying the rs2231142-A allele had higher UA levels than
that with the homozygous rs2231142-CC allele (Table 3).
In contrast, difference in UA levels was not significant in
nonobese patients carrying the aforementioned alleles.
In terms of frequency of hyperuricemia, the rs2231142-A
allele also exerted more effects on obese patients
(Figure 1).
Sexually dimorphic association of the ABCG2 SNPs
with UA levels
Our data showed a sexual difference in effects of rs2231142
on UA levels and frequency of hyperuricemia. The SNPMale Female p
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44.2  9.4 45.8  9.6 0.067
7.1 10.1 0.159
113.1  12.6 112.0  17.9 0.428
76.7  9.3 72.7  9.8 <0.001
201.7  34.3 195.7  37.1 0.073
50.0  12.0 61.6  13.5 <0.001
119.2  32.0 112.9  32.1 0.037
171.9  142.7 106.4  57.5 <0.001
24.7  3.0 23.6  3.6 <0.001
4.1 3.2 0.390
35.3 4.1 <0.001
7.1  1.4 5.4  1.3 <0.001
Triglyceride values were logarithmically transformed before sta-
ver, the untransformed data are shown.
nsity lipoprotein.
Figure 1 The rs2231142-A allele of the ABCG2 gene is
significantly associated with hyperuricemia in general, obese,
and male population samples. Hyperuricemia was diagnosed
according to the following criteria: male high:UA  7 mg/dL,
male low:UA < 7 mg/dL, female high:UA  6 mg/dL, female
low:UA < 6 mg/dL.
ABCG2 gene polymorphisms and uric acid levels 21rs2231142 influenced UA levels more strongly in males
(Table 3). In males with the rs2231142-A allele, hyper-
uremic conditions were also more likely to develop
(Figure 1).Table 3 The association between the ABCG2 single nucleotide p
and obesity.
ABCG2 rs2231142 UA levels
Means  SD (n)
Obese p** value
CC 6.46  1.65 (74)
CA 7.07  1.44 (81) 0.374
AA 6.98  1.75 (17)
CC
CA+AA 7.06  1.49 (98) 0.018
Man p* value
CC 6.86  1.49 (98)
CA 7.34  1.33 (116) 0.707
AA 7.25  1.64 (20)
CC
CA+AA 7.33  1.38 (136) 0.023
Obese (Woman) p* value
CC 5.48  1.19 (30)
CA 6.50  1.59 (30) 0.565
AA 6.04  1.30 (7)
CC
CA+AA 6.42  1.53 (37) 0.01
Obese (Man) p* value
CC 7.13  1.59 (44)
CA 7.41  1.25 (51) 0.447
AA 7.64  1.78 (10)
CC
CA+AA 7.44  1.34 (61) 0.302
N: number of subjects; p* value: adjusted for age, BMI and smoking st
value: interaction p.Interaction of the ABCG2 SNPs with both sex and
obesity on UA levels
It became evident from our previous analyses that effects
of the rs2231142-A allele on UA levels were affected by
sex and obesity. As a result, we sought to elucidate
possible interactions between sex and obesity on UA levels
among carriers of different rs2231142 alleles. For fe-
males, significant interactions were found between
rs2231142 and obesity on UA levels (Table 3). In contrast,
no significant differences of UA levels were observed in
nonobese females with different rs2231142 genotypes
(Table 3). Because the effects of rs2231142 on UA levels
were not observed in female and nonobese patients, we
then sought to examine the interaction term between
nonobese females and the other patients. When obese
females were grouped with the other male patients and
compared with nonobese females, we still noted signifi-
cantly higher UA levels for patients carrying the
rs2231142-A allele in this large group (Figure 2). Moreover,
a significant interaction was noted between the two
groups (Figure 2, others vs. nonobese females, interaction
p Z 0.0189), indicating that the ability of rs2231142 in
regulating UA levels could be greatly attenuated in non-
obese females.olymorphism rs2231142 and uric acid levels in subgroups of sex
UA levels Interaction
Means  SD (n) p# value
Nonobese p** value
5.78  1.45 (134)
6.25  1.67 (121) 0.712 0.554
5.94  1.46 (24)
6.20  1.63 (145) 0.185 0.229
Woman p* value
5.28  1.19 (110)
5.55  1.40 (86) 0.393 0.87
5.54  1.19 (21)
5.54  1.36 (107) 0.123 0.477
Nonobese (Woman) p* value
5.20  1.19 (80)
5.03  0.97 (56) 0.588
5.29  1.09 (14)
5.08  0.99 (70) 0.75
Nonobese (Man) p* value
6.63  1.38 (54)
7.30  1.40 (65) 0.861
6.85  1.47 (10)
7.24  1.41 (75) 0.038
atus; p** value: adjusted for age, sex, BMI and smoking status; p#
Figure 2 The rs2231142-A allele is not associated with UA
levels in nonobese female patients.
22 S.-T. Cheng et al.Discussion
We confirmed association of the SNP rs2231142 with UA
levels and hyperuricemia in a Taiwanese cohort, and found
it predominantly in males. Furthermore, obesity alone
determined serum UA levels regardless of ABCG2 genotypes
or sex, and we were the first to find an association between
the rs2231142-A allele and hyperuricemia in obese patients.
A previous study shows that serum UA concentration has
a 63% heritability.9 Indeed, a meta-analysis identifies
ABCG2 among nine loci associated with UA concentration.22
In these studies, rs2231142 is the only SNP consistently
associated with both hyperuricemia and gout. We
confirmed the association with hyperuricemia except in
nonobese females.
Previous studies show substantial interaction between
genotypes and sex on UA levels. For instance, rs2231142 is
consistently associated with UA concentration and gout in
males.5,16,22 Our data showed a similar interaction, as we
found significant association between rs2231142 and UA
levels in males.
We found significant association between rs2231142 and
hyperuricemia in obese patients. In a mouse model of
obesity, concentration of both ABCG2 and urate reabsorp-
tion transporter URAT1 increases significantly,30 suggesting
a link between enhanced urate reabsorption and obesity-
associated hyperuricemia. Although we did not measure
ABCG2 or URAT1 concentration, UA concentration was
higher in obese patients and was further enhanced in those
carrying the rs2231142-A allele. We hypothesized that
obesity readily reveals effect of rs2231142 on
hyperuricemia.
We uncovered an extra layer of interaction between sex,
obesity, and rs2231142 on UA levels. Our data showed
rs2231142-A was not associated with UA levels in nonobese
females. This difference might be due to specific physio-
logical characteristics of the nonobese females other than
that of estrogen, because it has been reported that estro-
gen does not increase renal clearance of serum UA in adult
women.31 Regarding the female hormonal effect on UA
levels, we did not observe significant differences betweenpremenopausal and menopausal female subgroups
(Supplementary Table 1). Alternatively, nonobesity may
have ameliorated hyperuricemia in rs2231142-A-carrying
females by compensating for reduced ABCG2 activities.
Whether it is due to metabolic or additional hormonal ef-
fect awaits further investigation, and a larger sample size is
needed to clarify the role of sex hormones on UA levels and
hyperuricemia in female patients.Limitation
Because of the relatively small sample size and high minor
allele frequency of rs2231142 in this study (Supplementary
Table 2), it might have had limited power to detect asso-
ciations between rs2231142 and UA. Still, we were able to
validate our results independently using multiple re-
gressions adjusted for confounding factors (Supplementary
Table 3). In addition, we also validated our results using
multiple testing corrections including full scan permuta-
tions (p Z 0.001 for 1000 permutations), Bonferroni
adjustment and false discovery rate (FDR) calculations
(rs2231142-C allele; both regression Bonferroni P and
regression FDR Z 5.7  104), thus strengthening the
conclusion that rs2231142 is indeed associated with serum
UA levels.Conclusion
A reduction-of-function SNP rs2231142 in the ABCG2 gene is
associated with hyperuricemia in a Taiwanese cohort. The
genetic determinants for hyperuricemia differ according to
sex and obesity status. The rs2231142-A allele has signifi-
cantly stronger association with hyperuricemia in male and
obese patients.Acknowledgments
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